AstraZeneca hands off epilepsy programs to Ovid; Amylyx scores priority review for ALS drug
Still recovering from a setback in its lead program, Ovid Therapeutics has turned to AstraZeneca for a suite of experimental epilepsy drugs.
Ovid is paying the Big Pharma partner $5 million in cash and $7.5 million in stock to access a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate OV350. AstraZeneca stands to receive milestones adding up to more than $200 million and retains an option for a strategic collaboration.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.